- IGC Pharma (IGC, Financial) reports a revenue decline to $1.2 million in FY2025, down from $1.3 million in FY2024, but significantly reduces net loss to $7.1 million.
- Phase 2 CALMA trial of IGC-AD1 shows promising results, with substantial reductions in agitation and sleep disturbances in Alzheimer's patients.
- Strategic advancements include expanding clinical trial sites, developing AI-based diagnostic tools, and raising $4.64 million through equity placements.
IGC Pharma (IGC), a clinical-stage biotechnology firm, has released its financial and operational highlights for the fiscal year 2025. Reporting a revenue of $1.2 million, a slight decrease from $1.3 million the previous year, the company notably reduced its net loss to $7.1 million or $0.09 per share, compared to $13 million or $0.22 per share in FY2024.
The company's lead drug candidate, IGC-AD1, showed promising interim results in the Phase 2 CALMA trial, with significant reductions in both agitation and sleep disturbances for Alzheimer's patients. This progress addresses a considerable unmet need, given that 76% of the 50 million Alzheimer’s patients globally experience agitation and few effective treatments exist.
Operationally, IGC Pharma made significant advancements by expanding its clinical trial sites across North America, developing MINT-AD, an AI-based diagnostic tool for Alzheimer's, and securing two awards in the PREPARE Challenge. Additionally, they successfully raised $4.64 million through equity placements and ATM offerings.
The company's strategic outlook for FY2026 includes completing the CALMA Phase 2 trial, launching a second study to evaluate the disease-modifying effects of IGC-AD1, and deploying a beta version of MINT-AD. Despite the revenue decline, these developments signal IGC Pharma's commitment to pioneering Alzheimer's treatment innovations.
